The size of the Asia Pacific Schizophrenia Drugs Market was worth USD 1.43 billion in 2021. This value is estimated to be growing at a CAGR of 2.78%, to reach USD 1.64 billion by 2026.
Schizophrenia is a central nervous system disorder that affects around 1% of the total global population. It is characterized by various symptoms including hallucinations and thought disorders. It could be due to genetic, environmental or chemical factors or sometimes due to a combination of them.
Increased prevalence of schizophrenia cases and increased healthcare expenditure are driving the market growth. Increased R&D projects in the healthcare segment and growing number of cases of alcohol and drug addiction are further fuelling the market growth. There has been a arise in the demand for sophisticated treatment by patients which is propelling the market growth. However, high investment costs and lack of awareness are restraining the market growth.
The market for Schizophrenia Drugs Agents is broadly categorized into therapeutic class and treatment. By therapeutic class the market is divided into second generation anti-psychotics, third generation anti-psychotics and others. Second and third generation anti-psychotics are the preferred line of treatment for schizophrenia. By treatment the market is classified into oral and injectable anti-psychotics. On the basis of geography, the market is analysed under various regions namely China, India, Japan, Australia and South Korea. Asia Pacific is expected to grow at a high CAGR.
Some of the major companies dominating the market, by their products and services include Johnson & Johnson, Sumitomo Dainippon, Eli Lilly, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Alkermes, Vanda Pharma, Allergan and Pfizer.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Therapeutic class
5.1.1 Introduction
5.1.2 Second generation anti-psychotics
5.1.2.1 Risperdal
5.1.2.2 Invega
5.1.2.3 Zyprexa
5.1.2.4 Geodon
5.1.2.5 Seroquel
5.1.2.6 Latuda
5.1.2.7 Aristada
5.1.2.8 Fanapt
5.1.2.9 Saphris
5.1.2.10 Vraylar
5.1.3 Third generation anti-psychotics
5.1.4 Others
5.1.5 Y-o-Y Growth Analysis, By Therapeutic class
5.1.6 Market Attractiveness Analysis, By Therapeutic class
5.1.7 Market Share Analysis, By Therapeutic class
5.2 Treatment
5.2.1 Introduction
5.2.2 Oral anti-psychotics
5.2.3 Injectable anti-psychotics
5.2.4 Y-o-Y Growth Analysis, By Treatment
5.2.5 Market Attractiveness Analysis, By Treatment
5.2.6 Market Share Analysis, By Treatment
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Therapeutic class
6.1.3.3 By Treatment
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Therapeutic class
6.1.4.3 By Treatment
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 Therapeutic class
6.1.5.3 By Treatment
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Johnson & Johnson
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Bristol-Myers Squibb
8.3 AstraZeneca
8.4 Sumitomo Dainippon
8.5 Eli Lilly
8.6 Alkermes
8.7 Vanda Pharma
8.8 Allergan
8.9 Pfizer
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
